TECH — BIO-TECHNE Corp

—
Nasdaq · Health Care · Biotechnology · CIK 842023 ·
Last close
$72.63
Market Cap
$11.41B
52W High
$72.86
52W Low
$43.03
ADV30
3,044,004
Next earnings
2026-11-09

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 299,712,000 196,623,000 36,603,000 28,293,000 2,636,820,000 350,036,000 471,131,000
Jun 2026 321,192,000 211,394,000 94,997,000 54,621,000 2,586,726,000 264,712,000 478,505,000
Mar 2026 311,415,000 208,288,000 75,495,000 51,047,000 2,550,601,000 209,819,000 465,297,000
Dec 2025 295,877,000 191,277,000 54,461,000 38,009,000 2,522,699,000 172,879,000 511,710,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$292,073,000
Investing CF
$-18,190,000
Financing CF
$-169,114,000
CapEx
$-28,850,000
Dividends Paid
$-49,916,000
Buybacks
$-41,675,000
EPS Diluted TTM
$1.15
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$1,144,188,000
Inventory
$195,744,000
Receivables
$216,585,000
ST Investments
$0
EBIT TTM
$250,310,000
Pretax Income TTM
$240,680,000
Interest Exp TTM
$9,630,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,228,195,968
EBITDA
$322,436,992
Free Cash Flow
$272,623,744
Enterprise Value
$11,368,582,144
Total Cash
$350,036,000
Total Debt
$285,555,008
Shares Out
157,055,564
Trailing EPS
$1.16
Book Value
$13.79
ROE
8.3%
ROA
6.4%
Div Yield
0.44%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 1,215,039,000 272,611,000 181,862,000 2,586,726,000 478,505,000 2,108,221,000 292,073,000
Jun 2025 1,219,635,000 242,804,000 73,400,000 2,557,868,000 639,060,000 1,918,808,000 287,556,000
Jun 2024 1,159,060,000 246,401,000 168,105,000 2,703,867,000 635,017,000 2,068,850,000 298,981,000
Jun 2023 1,136,702,000 290,998,000 285,263,000 2,638,692,000 672,176,000 1,966,516,000 254,393,000

TTM Snapshot

Revenues TTM
$1,215,039,000
NetIncome TTM
$181,862,000
OpCashFlow TTM
—
Assets (Latest)
$2,550,601,000
Forward EPS
$2.31

Max Pain — expiry 2027-01-15

max pain strike: $55.00 · spot: $72.75 · call oi: 25,595 · put oi: 949
Expected Move to 2027-01-15: ±$2.66 (3.66%) — implied range $70.09 – $75.41 · ATM straddle on $75.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —
RGEN REPLIGEN CORP $10.30B $162.18 —
QGEN QIAGEN N.V. $10.27B $49.75 —
PCVX Vaxcyte, Inc. $9.40B $59.40 —

News headlines (Yahoo Finance, 1h cache)

TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
2026-11-09 12:50 · Yahoo
Bio-Techne (TECH), What Is Behind The Fresh Attention Now?
2026-11-04 19:10 · Yahoo
BIO-TECHNE DECLARES DIVIDEND
2026-11-04 01:30 · Yahoo
2 high-flying stocks worth your attention and 1 we turn down
2026-11-03 12:13 · Yahoo
Stocks rebound as oil prices sink, Anthropic releases Q3 financials: AlphaCheck
2026-11-02 15:00 · Yahoo
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
2026-11-02 11:44 · Yahoo
Alphabet tumbles, software and cybersecurity stocks sink as earnings disappoint: AlphaCheck
2026-10-29 13:53 · Yahoo
What You Need to Know Ahead of Bio-Techne’s Earnings Release
2026-10-26 14:15 · Yahoo
1 Unpopular Stock That Should Get More Attention and 2 We Question
2026-10-09 14:43 · Yahoo
Bio-Techne opens GMP small molecule facility in Bristol, UK
2026-10-09 11:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.